USFDA approves Zydus Lifesciences' generic cancer therapy capsules

15 Dec 2023 , 09:44 AM

On Thursday, Zydus Lifesciences Ltd. announced that the US health regulatory has granted its generic version of the cancer treatment medication Cyclophosphamide capsules final approval. Zydus Lifesciences stated in a regulatory filing that the US Food and Drug Administration (USFDA) has approved Cyclophosphamide capsules in strengths of 25 mg and 50 mg.

It also stated that the medication will be produced in the group’s formulation manufacturing plant located in the Ahmedabad Special Economic Zone, India.

One chemotherapy drug that suppresses the proliferation of cancer cells is cyclophosphamide. According to the manufacturer, it treats leukaemia, lymphoma, myeloma, breast cancer, and ovarian cancer.

Zydus Lifesciences said that cyclophosphamide capsules, both 25 mg and 50 mg, achieved yearly sales of USD 6 million in the US, citing IQVIA MAT (moving annual total) statistics from October 2023.

For feedback and suggestions, write to us at [e-mail]